Generic semaglutide vs Ozempic vs Wegovy in Canada

Last clinically reviewed by Dr. Mark BroussenkoMD, April 29, 2026.

Now that generic semaglutide is available in Canada, the first question most people ask is: "Is it the same as Ozempic, and how much cheaper is it?"

The short answer: Health Canada reviewed the generic and confirmed it works the same way as Ozempic in the body for its authorized indication. It is expected to cost 75 to 85 percent of Ozempic at launch. The longer answer involves three separate Health Canada authorizations (Ozempic, the generic from Dr. Reddy's Laboratories, and Wegovy), each approved for a different use and priced differently.

This article covers how Health Canada decides a generic is equivalent to a brand-name product, why "same ingredient" does not always mean "same approved use," the side-by-side pricing as of April 2026, and the practical differences between the three products.

What "generic version" means in regulatory terms

A Health Canada-authorized generic contains the same active ingredient as the brand-name product, at the same strength, in a comparable form. Health Canada reviews the generic against the same criteria as the original, then issues approval once the submission passes.

One detail worth knowing: Novo Nordisk makes semaglutide using a biological process (growing it in living cells). Dr. Reddy's Laboratories makes the first authorized generic using a chemical process (building the molecule from scratch). The two manufacturing routes are different, but Health Canada's Regulatory Decision Summary for Dr. Reddy's semaglutide injection confirms that the generic was "considered equivalent to the Canadian Reference Product" after reviewing quality data, clinical data, and labelling.

The bottom line: Health Canada treats the generic as interchangeable with Ozempic within its defined acceptance ranges.

Bioequivalence: what Health Canada actually measures

"Bioequivalent" is not a marketing term. It is a standard defined by Health Canada.

To approve a generic, Health Canada compares two things between the generic and the brand-name product:

• Absorption: how much of the treatment the body absorbs over time (technically called AUC, or area under the curve)
• Level: the highest concentration the treatment reaches in the body (technically called Cmax)

For both, the generic must fall within 80 to 125 percent of the brand-name product's results. If it falls outside that range, it does not get approved.

For a small group of treatments with very narrow safety margins, Health Canada tightens that range to 90 to 112 percent. Semaglutide is not in that narrow-margin group, so the standard 80 to 125 percent range applies.

These are strict requirements, not loose guidelines.

Same active ingredient does not mean same authorized use

This is the most misunderstood part of the generic semaglutide conversation.

Ozempic, the generic from Dr. Reddy's, and Wegovy all contain semaglutide. But Health Canada does not approve a molecule for every possible use at once. It approves each product for a specific indication. Ozempic and the first authorized generic share the same Health Canada-authorized indication. Wegovy is approved separately for chronic weight management (at certain BMI thresholds), plus it received an additional cardiovascular risk authorization in late 2024.

Because each approval is tied to a specific use, the generic from Dr. Reddy's is not an authorized substitute for Wegovy. Insurance coverage and provincial drug plan listings follow the approved use, not the ingredient name.

Side-by-side: Ozempic, generic semaglutide, and Wegovy

Price comparison (April 2026)

Pricing in Canada follows the pan-Canadian Pharmaceutical Alliance (pCPA) tiered framework. The first generic is priced at 75 to 85 percent of the brand reference. Two generics on the market drops the tier to about 50 percent. Three or more generics drops it to roughly 35 percent. Health Canada notes that generics are typically 45 to 90 percent cheaper than branded versions over time.

‍

Cash-pay patients without insurance see the largest cost reduction as more generics enter the market. Coverage outcomes for the generic depend on whether private and public plans list it under the same limited-use criteria they apply to Ozempic. Health Canada is currently reviewing eight additional generic semaglutide submissions, so the pricing tier is expected to fall further over the next year.

Will the injection feel different?

Possibly, but any differences are minor.

The pen device from Dr. Reddy's is not the same device as Novo Nordisk's FlexTouch pen used for Ozempic and Wegovy. The injection mechanism, button feel, and needle attachment process may differ. Full device specifications from Dr. Reddy's are still being finalized at the time of publication.

Inactive ingredients (like buffers and preservatives) may also differ slightly between the generic and branded versions. That is one reason a small number of patients notice minor differences during a switch, such as injection-site comfort. These differences should not change how the treatment works.

Questions to discuss with a licensed healthcare provider

Patients considering the generic may find these questions useful in a conversation with a licensed healthcare provider:

• Is the generic from Dr. Reddy's available through my pharmacy yet, or is supply still limited?
• Will my provincial drug plan cover the generic under the same limited-use criteria as Ozempic?
• If I am currently stable on Ozempic, is there a clinical reason to stay on it rather than switch?
• Does my private insurance formulary distinguish between Ozempic and the generic?
• If my goal is weight management, which authorization scope applies, and what does that mean for coverage of Wegovy?

FAQs

Is generic semaglutide the same as Ozempic?

The active ingredient and strength are the same. Health Canada authorized the first generic semaglutide (manufactured by Dr. Reddy's Laboratories) on April 28, 2026 after confirming it absorbs and peaks in the body within 80 to 125 percent of Ozempic's range. Practical differences include the injector device, the inactive ingredients, and the manufacturer.

Is generic semaglutide approved for weight management in Canada?

No. The April 2026 authorization does not cover chronic weight management. Wegovy holds the Health Canada authorization for that indication. The first authorized generic does not carry that authorization.

How much cheaper is generic semaglutide than Ozempic?

Under the pCPA framework, the first generic is priced at 75 to 85 percent of Ozempic, which translates to roughly CA$190 to CA$340 per month at launch (compared to CA$250 to CA$400 for Ozempic, as of April 2026). Health Canada notes that generics are typically 45 to 90 percent cheaper than branded versions over time. Further price reductions are expected as additional generics are authorized.

Can my pharmacist switch me from Ozempic to the generic automatically?

Provincial pharmacy regulations vary. In most provinces, pharmacist-led substitution is permitted unless the prescriber has written "no substitution" or "dispense as written" on the prescription.

Why is Wegovy more expensive than Ozempic if both contain semaglutide?

Health Canada approves products for specific uses, not molecules. Wegovy has a separate approval for chronic weight management and a separate cardiovascular risk approval. Pricing and insurance coverage follow the approved use, not the ingredient. That is why Wegovy and Ozempic sit in different pricing structures even though they contain the same active ingredient.